This funded technology startup has developed speech synthesis and translation solutions through R&D and iits now ready to sell its ts assets, IP and related technology to a strategic partner. The company has unique tools for ultra-natural prosody tuning and cross-language voice transport, the company serves video and audio production and translation; digital assistants; multimodal display for commercial and museum use; and speech prosthetics for healthcare. The IP and technology can also create a range of in-person and online speech translation products, including facilities for multilingual online meetings.

The company assesses that speech is a massive and accelerating market, with no limits in sight. However, having exhausted its capital in the wake of lengthy development efforts and serious health challenges, it has decided to sell its valuable intellectual property and software assets. Its IP and technology are in the following areas:

Speech-to-Speech Translation (S2S)
The company’s initial focus was in speech-to-speech translation, with several software offerings for mobile, watch, and desktop. The system’s flexible and powerful framework allows modular substitution of major components – for speech recognition, text translation, and text-to-speech; enables online conversations among multiple languages, in which each participant speaks, hears, and reads in the native language; and provides unique social networking facilities. All related software is now available for acquisition. Additionally, the company is selling four patents relevant to speech-to-speech translation:

Automatic Speech Recognition (ASR)Automatic Speech Recognition (ASR) is a necessary component of Speech-to-Speech Translation (S2S). The company has six patents in this area. Text-to-Speech (TTS)

Another component of Speech-to-Speech Translation (S2S) is speech synthesis, or Text-to-Speech (TTS). This area became the company’s central focus. The company has six patents it believes are crucial to success in this area.

Overall the company believes that its patent portfolio is essential to monetice in a wide range of commercial offerings currently being sold and developed.